The cardiac sarcoplasmic/endoplasmic reticulum calcium ATPase: A potent target for cardiovascular diseases

Nature Clinical Practice Cardiovascular Medicine

Volumn 5, Issue 9, 2008, Pages 554-565

  Kawase, Yoshiaki ^a   Hajjar, Roger J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ADENOVIRUS VECTOR; BETA 2 ADRENERGIC RECEPTOR; CALCIUM ION; ISOPROTEIN; PHOSPHOLAMBAN; POTASSIUM ION; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 1B; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 2A; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 2B; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 2C; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 3A; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 3B; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 3C; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 3D; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 3E; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 3F;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR GENE THERAPY; CELL PROLIFERATION; CORONARY ARTERY BLOOD FLOW; DOWN REGULATION; DRUG MECHANISM; ENERGY CONSUMPTION; ENZYME INHIBITION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC REGULATION; HEART ARRHYTHMIA; HEART CONTRACTION; HEART FAILURE; HEART FUNCTION; HEART HYPERTROPHY; HEART MUSCLE ISCHEMIA; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; REPERFUSION INJURY; REVIEW; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ARRHYTHMIAS, CARDIAC; CALCIUM; CALCIUM SIGNALING; CALCIUM-BINDING PROTEINS; CARDIOMEGALY; CARDIOVASCULAR DISEASES; CELL PROLIFERATION; CORONARY CIRCULATION; DEPENDOVIRUS; ENERGY METABOLISM; GENE THERAPY; GENETIC VECTORS; HUMANS; ISOENZYMES; MUSCLE, SMOOTH, VASCULAR; MYOCARDIAL CONTRACTION; MYOCARDIUM; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; UP-REGULATION;

EID: 50649097202     PISSN: 17434297     EISSN: 17434300     Source Type: Journal    
DOI: 10.1038/ncpcardio1301     Document Type: Review

References (124)

1. Rosamond W et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee (2007) Heart disease and stroke statistics - 2008 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117; e25-e146
2. 2+-dependent adenosine triphosphatase from rat cardiac sarcoplasmic reticulum: Regulation of its expression by pressure overload and developmental stage. J Clin Invest 83: 1102-1108
3. 2+-ATPase and phospholamban mRNA expression in response to pressure overload and thyroid hormone. Proc Natl Acad Sci USA 86: 2966-2970
4. de la Bastie D et al. (1990) Function of the sarcoplasmic reticulum and expression of its Ca2(+)-ATPase gene in pressure overload-induced cardiac hypertrophy in the rat. Circ Res 66 554-564
5. Mercadier JJ et al. (1990) Altered sarcoplasmic reticulum Ca2(+)-ATPase gene expression in the human ventricle during end-stage heart failure. J Clin Invest 85: 305-309
6. Dharmsathaphorn K and Pandol SJ (1986) Mechanism of chloride secretion induced by carbachol in a colonic epithelial cell line. J Clin Invest 77: 348-354
7. del Monte F and Hajjar RJ (2003) Targeting calcium cycling proteins in heart failure through gene transfer. J Physiol 546: 49-61
8. 2+)-ATPase and inositol 1,4,5-trisphosphate receptor isoforms in vascular endotheiiai cells. Cell Calcium 25: 371-380
9. 2+)-ATPase. Circulation 101: 790-796
10. Miyamoto MI et al. (2000) Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure. Proc Natl Acad Sci USA 97: 793-798
11. Hui HP et al. (2006) Adeno-associated viral gene transfer of SERCA2a improves heart function in chronic congestive heart failure rats [Chinese]. Zhoonghua Xin Xue Guan Bing Za Zhi 34: 357-362
12. Pathak A et al. (2005) Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase 1. Circ Res 96: 756-766
13. Bers DM (2002) Cardiac excitation-contraction coupling. Nature 415: 198-205
14. Carr AN et al. (2002) Type 1 phosphatase, a negative regulator of cardiac function. Mol Cell Biol 22: 4124-4135
15. 2+-ATPase 2 isoform (SERCA2c). Biochem J 395: 249-258
16. 2+ signaling and control of growth and proliferation. Biol Cell 96: 55-68
17. 2+ ATPase isoforms and their role in muscle physiology and pathology. Ann N Y Acad Sci 853: 251-259
18. 2+ATPase of sarcoplasmic reticulum: Expression in developing skeletal muscle. J Biol Chem 262: 3768-3774
19. 2+)-ATPass and alpha-smooth muscle actin gene expression in aortas of normotensive and spontaneously hypertensive rats. Circ Res 72: 341-348
20. Lytton J et al. (1992) Functional comparisons between isoforms of the sarcoplasmic or ondoplasmic reticulum family of calcium pumps. J Blol Chem 267: 14483-14489
21. 2+-ATPase gene transfer reduces vascular smooth muscle cell proliferation and neointima formation in the rat. Circ Res 97: 488-495
22. 2+ pump during differentiation of BG3H1 muscle cells. Biochim Biophys Acta 1173: 188-194
23. Swynghedauw B (1986) Developmental and functional adaptation of contractile proteins in cardiac and skeletal muscles. Physiol Rev 66: 710-771
24. 2+-ATPase and phospholamban mRNAs are expressed in chronically stimulated rabbit fast-twitch muscle. Eur J Biochem 185: 51-54
25. Briggs FN et al. (1990) Ca-ATPase isozyme expression in sarcoplasmic reticulum is altered by chronic stimulation of skeletal muscle. FEBS Lett 259: 269-272
26. MacLennan DH and Kranias EG (2003) Phospholamban: A crucial regulator of cardiac contractility. Nat Rev Mol Cell Biol 4: 566-577
27. 2+)-ATPase activity of cardiac sarcoplasmic reticulum from dilated cardiomyopathy patients compared with patients with nonfailing hearts. Circulationm 92 3220-3228
28. 2+)-ATPase in failing and nonfalling human myocardium. Circ Res 75: 434-442
29. Arai M et al. (1993) Alterations in sarcoplasmic reticulum gene expression in human heart failure: A possible mechanism for alterations in systolic and diastolic properties of the failing myocardium. Circ Res 72: 463-469
30. Frank K et al. (1998) Frequency dependent force generation correlates with sarcoplasmic calcium ATPase activity in human myocardium. Basic Res Cardiol 93: 405-411
31. del Monte F et al. (1999) Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a. Circulation 100: 2308-2311
32. Hoshijima M et al. (2002) Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat Med 8: 864-871
33. O'Donnell JM et al. (2001) Tight control of exogenous SERCA expression is required to obtain acceleration of calcium transients with minimal cytotoxic effects in cardiac myocytes. Circ Res 88: 415-421
34. 1+)-ATPase. Circ Res 81 145-153
35. 2+ ATPase gene in the heart of transgenic mice accelerates calcium transients and cardiac relaxation. J Clin Invest 100 380-389
36. 2+-ATPase increases cardiac contractility in transgenic mouse hearts. Circ Res 83: 1205-1214
37. 2+-ATPase. Circ Res 83: 889-897
38. Terracciano CM et al. (2002) Overexpression of SERCA2a accelerates repolarisation in rabbit ventricular myocytes. Cell Calcium 31 299-305
39. Du XJ et al. (2000) Age-dependent cardiomyopathy and heart failure phenotype in mice overexpressing beta(2)-adrenergic receptors in the heart. Cardiovasc Res 48: 448-454
40. Liggert SB et al. (2000) Early and delayed consequences of β2-adrenergic receptor overexpression in mouse hearts. Critical rate for expression level. Circulation 101: 1707-1714
41. Sakata S, et al. (2007) Targeted gene trunsfer increases contractility and decreases oxygen cost of contractility in normal rat hearts. Am J Physiol Heart Circ Physiol 292: H2356-2363
42. Sakata S et al. (2007) Restoration of mechanical and energetic function in failing aortic-banded rat hearts by gene transfer of calcium cycling proteins. J Mol Cell Cardiol 42: 852-861
43. 2+) ATPase modifies the transition from hypertrophy to early heart failure. Circ Res 89: 422-429
44. 2+)-ATPase improves myocardial contractility in diabetic cardiomyopathy. Diabetes 51: 1166-1171
45. Sakata S et al. (2006) Mechanical and metabolic rescue in a type II diabetes model of cardiomyopathy by targeted gene transfer. Mol Ther 13: 987-996
46. Kawase Y et al. (2008) Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J Am Coll Cardio 51: 1112-1119
47. Muller OJ et al. (2003) Transgenic rat hearts overexpressing SERCA2a show improved contractility under baseline conditions and pressure overload. Cardiovasc Res 59: 380-389
48. Chu D et al. (2003) Direct comparison of efficiency and stability of gene transfer into the mammalian heart using adeno-associated virus versus adenovirus vectors. J Thorac Cardiovasc Surg 126: 671-679
49. Yang Y et al. (1994) Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 91: 4407-4411
50. Yeh P et al. (1996) Efficient dual transcomplementation of adenovirus E1 and E4 regions from a 293-derived call line expressing a minimal E4 functional unit. J Virol 70: 559-565
51. Manno CS et al. (2006) Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 12: 342-347
52. Bassani JW et al. (1994) Relaxation in rabbit and rat cardiac cells: Species-dependent differences in cellular mechanisms. J Physiol 476: 279-293
53. Hasenfuss G (1998) Alterations of calcium-regulatory proteins in heart failure. Cardiovasc Res 37: 274-289
54. Sakata S et al. (2007) Preservation of mechanical and energetic function after adenoviral gene transfer in normal rat hearts. Clin Exp Pharmacol Physiol 34: 1300-1306
55. 2+) overload-induced failing hearts. Jpn J Physiol 52: 163-171
56. 2+)-ATPase in a rat model of heart failure. Circulation 104: 1424-1429
57. Sami MH (1991) Sudden death in congestive heart failure. J Clin Pharmacol 31: 1081-1084
58. Rodriguez B et al. (2006) Modeling cardiac ischemia. Ann NY Acad Sci 1080: 395-414
59. Brooks WW et al. (1995) Reperfusion induced arrhythmias following ischaemia in intact rat heart: Role of intracellular calcium. Cardiovasc Res 29: 536-642
60. Asano G et al. (2003) Pathogenesis and protection of ischemia and reperfusion injury in myocardium. J Nippon Med Sch 70: 384-392
61. del Monte F et al. (2004) Abrogation of ventricular arrhythmias in a model of ischemia and reperfusion by targeting myocardial calcium cycling. Proc Natl Acad Sci USA 101: 5622-5627
62. Matsumura K et al. (2000) Protein kinase C is involved in cardioprotective effects of ischemic preconditioning on infarct size and ventricular arrhythmia in rats in vivo. Mol Cell Biolchem 214 39-45
63. 2+-ATPase delays myocardial failure after myocardial infarction in rats at a cost of increased acute arrhythmias. Circulation 109: 1898-1903
64. Prunier F et al.: Prevention of ventricular arrhythmias with SERCA2a overexpression in a porcine model of ischemia reperfusion. Circulation, in press
65. Meerson FZ et al. (1987) The role of lipid peroxidation in pathogenesis of arrhythmias and prevention of cardiac fibrillation with antioxidants. Basic Res Cardiol 82: 123-137
66. Bernier M et al. (1989) Reperfusion arrhythmias: Dose-related protection by anti-free radical interventions. Am J Physiol 256 H1344-H1352
67. Adachi T et al. (2004) S-Glutathiolation by peroxynitrite activates SERCA during arterial relaxation by nitric oxide. Nat Med 10: 1200-1207
68. Hiranandani N et al. (2006) SERCA overexpression reduces hydroxyl radical injury in murine myocardium. Am J Physiol Heart Circ Physiol 291: H3130-H3135
69. Yu J et al. (2006) Insulin improves cardiomyocyte contractile function through enhancement of SERCA2a activity in simulated ischemia/ reperfusion. Acta Pharmacol Sin 27: 919-926
70. Moens AL et al. (2005) Myocardial ischemia/reperfusion-injury, a clinical view on a complex pathophysiological process. Int J Cardiol 100: 179-190
71. Abbo KM et al. (1995) Features and outcome of no-reflow after parcutaneous coronary intervention. Am J Cardiol 75: 778-782
72. Hadri L et al. (2007) SERCA2a overexpression induces eNOS activation in human coronary artery endothelial cells Circ Res 101: E65-E65
73. Bolli R (2001) Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: An overview of a decade of research. J Mol Cell Cardiol 33: 1897-1918
74. Li Q et al. (2003) Gene therapy with inducible nitric oxide synthase protects against myocardial infarction via a cyclooxygenase-2-dependent mechanism. Circ Res 92: 741-748
75. 2+)-ATPase function and lowers tyrosine nitration in hypercholesterolemia and improves nitric oxide-induced relaxation. Circ Res 90: 1114-1121
76. Bolli R (2007) Preconditioning: A paradigm shift in the biology of myocardial ischemia. Am J Physiol Heart Circ Physiol 292: H19-H27
77. Murry CE et al. (1986) Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation 74: 1124-1136
78. Canty JM Jr et al. (2004) Hibernating myocardium: Chronically adapted to ischemia but vulnerable to sudden death. Circ Res 94 1142-1149
79. Fallavollita JA et al. (2004) Spatial heterogeneity of endocardial voltage amplitude in viable, chronically dysfunctional myocardium. Basic Res Cardiol 99: 212-222
80. Canty JM Jr and Fallavollita JA (2005) Hibernating myocardium. J Nucl Cardiol 12: 104-119
81. Fallavollita JA et al. (2005) Mechanism of sudden cardiac death in pigs with viable chronically dysfunctional myocardium and ischemic cardiomyopathy. Am J Physiol Heart Circ Physiol 289: H2688-H2696
82. Podio V et al. (2002) Prognosis of hibernating myocardium is independent of recovery of function: Evidence from a routine based follow-up study. Nucl Med Commun 23: 933-942
83. 2+)-ATPase, phospholamban, and HSP-70 expression in chronic hibernating myocardium. Am J Physiol 277: H1418-H1428
84. Wiggers H et al. (2005) Suppressed phospholamban levels differentiate irreversibly dysfunctional from hibernating myocardium in humans. Scand Cardiovasc J 39: 55-59
85. Deindl E et al. (1998) Reduced contractile function characteristic of hibernating human heart is not mediated by phospholamban. Ann NY Acad Sci 853: 270-272
86. Kjekshus J (1990) Arrhythmias and mortality in congestive heart failure. Am J Cardiol 65: 421-481
87. Akar FG and Rosenbaum DS (2003) Transmural electrophysiological heterogeneities underlying arrhythmogenesis in heart failure. Circ Res 93: 638-645
88. Janse MJ (2004) Electrophysiological changes in heart failure and their relationship to arrthythmogenesis. Cardiovasc Res 61: 208-217
89. Terracciano CM et al. (1997) The effects of changes to action potential duration on the calcium content of the sarcoplasmic reticulum in isolated guinea-pig ventricular myocytes. Pflugers Arch 433 542-544
90. 2+ exchanger in end-stage human heart failure. Circ Res 75: 443-453
91. O'Rourke B et al. (1999) Mechanisms of altered excitation-contraction coupling in canine tachycardia-induced heart failure, I: Experimental studies. Circ Res 84: 562-570
92. 2+) leak through ryanodine receptor in heart failure. Circulation 102: 2131-2136
93. Vermeulen JT et al. (1994) Triggered activity and automaticity in ventricular trabeculae of failing human and rabbit hearts. Cardiovasc Res 28: 1547-1554
94. 2+ exchanger in reverse remodeling: Relevance for LVAD-recovery. Ann NY Acad Sci 1099: 349-360
95. Poelzing S and Rosenbaum DS (2004) Altered connexin43 expression produces arrhythmia substrate in heart failure. Am J Physiol Heart Circ Physiol 287: H1762-H1770
96. Akar FG et al. (2004) Mechanisms underlying conduction slowing and arrhythmogenesis in nonischemic dilated cardiomyopathy. Circ Res 95: 717-725
97. Sakata S et al. (2007) Transcoronary gene transfer of SERCA2a increases coronary blood flow and decreases cardiomyocyte size in a type 2 diabetic rat model. Am J Physiol Heart Circ Physiol 292: H1204-H1207
98. Madigan JD et al. (2001) Time course of reverse remodeling of the left ventricle during support with a left ventricular assist device. J Thorac Cardiovasc Surg 121: 902-908
99. Akar FG et al. (2007) Dynamic changes in conduction velocity and gap junction properties during development of pacing-induced heart failure. Am J Physiol Heart Circ Physiol 293: H1223-H1230
100. Wagoner LE and Walsh RA (1996) The cellular pathophysiology of progression to heart failure. Curr Opin Cardiol 11: 237-244
101. Gupta S et al. (2007) Cardiac hypertrophy: Mechanisms and therapeutic opportunities. Antioxid Redox Signal 9: 623-652
102. 2+ affinity mutant of SERCA2a attenuates in vivo pressure overload cardiac hypertrophy. FASEB J 17: 61-63
103. Molkentin, JD et al. (1998) A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93: 215-228
104. Obata K et al. (2005) Overexpression of calmodulin induces cardiac hypertrophy by a calcineurin-dependent pathway. Biochem Blophys Res Commun 338: 1299-1305
105. Kuriyama M et al. (2006) A cell-permeable NFAT inhibitor peptide prevents pressure-overload cardiac hypertrophy. Chem Biol Drug Des 67: 238-243
106. 2+ response amplitude and duration. Nature 386: 855-858
107. 2+ signaling in cardiac myocyte excitation-transcription coupling. J Clin Invest 116: 676-682
108. Berridge MJ (1997) Elementary and global aspects of calcium signalling. J Physiol 499: 291-306
109. Nelson MT et al. (1995) Relaxation of arterial smooth muscle by calcium sparks. Science 270: 633-637
110. 26+ concentration in single vascular smooth muscle cells in situ. EMBO J 13: 5026-5031
111. 2+ transients in smooth muscle of pressurized rat resistance arteries during myogenic and agonist stimulation. J Physiol 518: 815-824
112. 2+) waves by UTP in rat cerebral artery smooth muscle cells. Am J Physiol Cell Physiol 279: C1528-C1539
113. 2+) handling in vascular smooth muscle cells is affected by proliferation. Arterioscler Thromb Vasc Biol 20: 1225-1235
114. Dolmetsch RE et al. (2001) Signaling to the nucleus by an L-type calcium channel-calmodulin complex through the MAP kinase pathway. Science 294: 333-339
115. 2+) channels. Circ Res 86: 760-767
116. Hardingham GE et al. (1997) Distinct functions of nuclear and cytoplasmic calcium in the control of gene expression. Nature 385: 260-265
117. Gomez MF et al. (2002) Opposing actions of inositol 1,4,5-trisphosphate and ryanodine receptors on nuclear factor of activated T-cells regulation in smooth muscle. J Biol Chem 277 37756-37764
118. Lipskaia L et al. (2003) Phosphatidylinositol 3-kinase and calcium-activated transcription pathways are required for VLDL-induced smooth muscle cell proliferation. Circ Res 92: 1115-1122
119. Lin D et al. (1994) Constitutive expression of B-myb can bypass p53-induced Waf1/Cip1-mediated G1 arrest. Proc Natl Acad Sci USA 91: 10079-10083
120. 2+ signals and immunosuppression. Nature 383: 837-840
121. 2+)-ATPase gene expression in thoracic and abdominal aortas of normotensive and spontaneously hypertensive rats. J Biol Chem 268: 8325-8331
122. Rudic RD et al. (1998) Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling. J Clin Invest 101: 731-736
123. Sato J et al. (2000) eNOS gene transfer to vascular smooth muscle cells inhibits cell proliferation via upregulation of p27 and p21 and not apoptosis. Cardiovasc Res 47: 697-706
124. Amano K et al. (2003) Enhancement of ischemia-induced angiogenesis by eNOS overexpression. Hypertension 41: 156-162